We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
15 August 2018
Health Canada recently published two guidance documents, effective 23 May 2018, that address the reporting of adverse reactions to marketed health products (excluding blood and blood components and cells, tissues and organs).
First, Reporting Adverse Reactions to Marketed Health Products provides assistance on reporting adverse reactions to marketed health products, including good case management practices.
Second, Preparing and Submitting Summary Reports for Marketed Drugs and Natural Health Products addresses the format and content of annual summary reports and issue-related summary reports, as well as procedures for the submission of these reports to Health Canada.
For further information on this topic please contact Brandon Heard at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (firstname.lastname@example.org). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.